SG Americas Securities LLC Acquires Shares of 16,088 Inhibrx Biosciences, Inc. $INBX

SG Americas Securities LLC acquired a new stake in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 16,088 shares of the company’s stock, valued at approximately $1,271,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Boothbay Fund Management LLC boosted its holdings in shares of Inhibrx Biosciences by 179.2% during the 3rd quarter. Boothbay Fund Management LLC now owns 78,812 shares of the company’s stock valued at $2,654,000 after purchasing an additional 50,582 shares during the last quarter. Mark Asset Management LP bought a new position in shares of Inhibrx Biosciences during the 2nd quarter valued at about $243,000. Franklin Resources Inc. bought a new position in shares of Inhibrx Biosciences during the 2nd quarter valued at about $316,000. Readystate Asset Management LP boosted its holdings in shares of Inhibrx Biosciences by 534.1% during the 3rd quarter. Readystate Asset Management LP now owns 170,158 shares of the company’s stock valued at $5,731,000 after purchasing an additional 143,324 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Inhibrx Biosciences during the 3rd quarter valued at about $249,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Biosciences Stock Down 2.2%

Shares of NASDAQ:INBX opened at $62.35 on Wednesday. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 12.58. Inhibrx Biosciences, Inc. has a 12 month low of $10.81 and a 12 month high of $94.57. The company has a 50-day moving average price of $73.04 and a 200 day moving average price of $69.09. The company has a market cap of $910.93 million, a price-to-earnings ratio of -6.90 and a beta of 1.82.

Inhibrx Biosciences (NASDAQ:INBX) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($2.11) EPS for the quarter, missing analysts’ consensus estimates of ($2.08) by ($0.03). As a group, equities research analysts predict that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Reduce”.

Inhibrx Biosciences Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.